Macik BG - Search Results

1

Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa): results of a phase I study.

Macik BG, Lindley CM, Lusher J, Sawyer WT, Bloom AL, Harrison JF, Baird-Cox K, Birch K, Glazer S, Roberts HR. Macik BG, et al. Blood Coagul Fibrinolysis. 1993 Aug;4(4):521-7. doi: 10.1097/00001721-199308000-00001. Blood Coagul Fibrinolysis. 1993. PMID: 8218848 Clinical Trial.

2

Mechanism by which recombinant factor VIIa shortens the aPTT: activation of factor X in the absence of tissue factor.

Telgt DS, Macik BG, McCord DM, Monroe DM, Roberts HR. Telgt DS, et al. Among authors: macik bg. Thromb Res. 1989 Dec 1;56(5):603-9. doi: 10.1016/0049-3848(89)90268-5. Thromb Res. 1989. PMID: 2626745

3

Use of recombinant activated factor VII for treatment of a retropharyngeal hemorrhage in a hemophilic patient with a high titer inhibitor.

Macik BG, Hohneker J, Roberts HR, Griffin AM. Macik BG, et al. Am J Hematol. 1989 Nov;32(3):232-4. doi: 10.1002/ajh.2830320315. Am J Hematol. 1989. PMID: 2816918

4

Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.

Lindley CM, Sawyer WT, Macik BG, Lusher J, Harrison JF, Baird-Cox K, Birch K, Glazer S, Roberts HR. Lindley CM, et al. Among authors: macik bg. Clin Pharmacol Ther. 1994 Jun;55(6):638-48. doi: 10.1038/clpt.1994.80. Clin Pharmacol Ther. 1994. PMID: 8004880 Clinical Trial.

5

The use of high-dose intravenous gamma-globulin in acquired von Willebrand syndrome.

Macik BG, Gabriel DA, White GC 2nd, High K, Roberts H. Macik BG, et al. Arch Pathol Lab Med. 1988 Feb;112(2):143-6. Arch Pathol Lab Med. 1988. PMID: 2447856

6

Topical thrombin and acquired coagulation factor inhibitors: clinical spectrum and laboratory diagnosis.

Ortel TL, Charles LA, Keller FG, Marcom PK, Oldham HN Jr, Kane WH, Macik BG. Ortel TL, et al. Among authors: macik bg. Am J Hematol. 1994 Feb;45(2):128-35. doi: 10.1002/ajh.2830450206. Am J Hematol. 1994. PMID: 8141118 Review.

7

Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation.

Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Morrissey JH, et al. Among authors: macik bg. Blood. 1993 Feb 1;81(3):734-44. Blood. 1993. PMID: 8427965 Free article.

8

Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy.

Shami VM, Caldwell SH, Hespenheide EE, Arseneau KO, Bickston SJ, Macik BG. Shami VM, et al. Among authors: macik bg. Liver Transpl. 2003 Feb;9(2):138-43. doi: 10.1053/jlts.2003.50017. Liver Transpl. 2003. PMID: 12548507 Free article.

9

Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: a break from convention in need of controlled trials.

Caldwell SH, Chang C, Macik BG. Caldwell SH, et al. Among authors: macik bg. Hepatology. 2004 Mar;39(3):592-8. doi: 10.1002/hep.20123. Hepatology. 2004. PMID: 14999675 Review.

10

Designing a point-of-care program for coagulation testing.

Macik BG. Macik BG. Arch Pathol Lab Med. 1995 Oct;119(10):929-38. Arch Pathol Lab Med. 1995. PMID: 7487394 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

35 results

Search Page

Filters